National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Department of Health

Yasutaka Hoshino

Robert M Chanock

Albert Z Kapikian

Karen Midthun

Jorge Flores

Richard G Wyatt

Brian R Murphy

Timo Vesikari

Mary Elaine La Montagne, Legal Representative

Mario Gorziglia

Lone Simonsen

Irene Peres-Schael

David M Morens

John R La Montagne

The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human&#xd7; bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.

Hexavalent bovine rotavirus reassortant composition designed for use in developing countries

The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human&#xd7;bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.

Multivalent human-bovine rotavirus vaccine

The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.

Attenuated human rotavirus vaccine

A new method for producing live, attenuated rotavirus strains suitable for preparing a vaccine is described. It is demonstrated that a naturally attenuated rotavirus recovered from newborns or other individuals whos have undergone asymptomatic infection can be used for immunization or that a virulent rotavirus can be converted into an attenuated strain by substituting the conserved fourth rotavirus gene segments of a naturally attenuated rotavirus in the genome of the virulent rotavirus.

Vaccine against rotavirus diseases and method of preparing same

The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3.

Vaccine against rotavirus diseases

Growing community of inventors

Wheaton, MD, United States of America

Yasutaka Hoshino